Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BulbaMan who wrote (549)	12/19/2019 11:11:05 AM
From: scaram(o)uche	Read Replies (2) of 684

Cool. Both of our contributions to the thread have PD-1 plus CD27 agonist projects, Aduro's in partnership with Merck. Celldex's project (due in clinic 1H20) described here..... celldex.com Coincidence, just sold ADRO after the sting news. You have interest in April? edit: Just noticed that I had referred to it as a CD28xPD-1 in an earlier post, which is weird..... worked on CD27 (serology), and it's one of my faves.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next